Indian government plans to establish dynamic and balanced IPR policy
Even as US President Barack Obama is slated to be the chief guest at India's Republic Day Parade on January 26, action has revved up behind the scenes with the readying of the draft of the national Intellectual Property Rights policy, reports The Pharma Letter’s India correspondent.
The aim of the national Intellectual Property Rights (IPR) policy is to establish a dynamic, vibrant and balanced IP system in India that would foster innovation and creativity in a knowledge economy, and accelerate economic growth, employment and entrepreneurship.
Given the ever-growing IPR disputes with the USA, the draft framework has been prepared by an IPR think tank set up in November by the Department of Industrial Policy and Promotion (DIPP).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze